 | • レポートコード：QY2108PAL8815 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、132ページ • 納品方法：Eメール（納期：1日） • 産業分類：医薬品 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の当調査資料ではグローバルにおけるデュシェンヌ筋ジストロフィーの市場規模（2016年-2027年）と動向についてまとめました。中国市場については主要プレイヤーの市場シェア、デュシェンヌ筋ジストロフィーの種類別市場規模（エクソンディス、エンフラザ、トランスラーナ）、用途別市場規模（病院、診療所、在宅医療）も掲載しています。他に、北米・アメリカ市場、ヨーロッパ市場、アジア太平洋・日本市場、中南米市場、中東・アフリカ市場の市場規模、グローバル市場機会・課題・リスク要因、バリューチェーン・販売チャネル、主要プレイヤーの情報なども掲載しています。 ・調査の概要 ・調査のサマリー ・世界のデュシェンヌ筋ジストロフィー市場動向 ・グローバル主要プレイヤーの競争状況・市場シェア ・世界におけるデュシェンヌ筋ジストロフィーの種類別市場規模（2016年-2027年）：エクソンディス、エンフラザ、トランスラーナ ・世界におけるデュシェンヌ筋ジストロフィーの用途別市場規模（2016年-2027年）：病院、診療所、在宅医療 ・デュシェンヌ筋ジストロフィーの中国市場分析 - デュシェンヌ筋ジストロフィーの中国市場規模（2016年-2027年） - 中国におけるデュシェンヌ筋ジストロフィーの主要プレイヤー別市場シェア - 中国におけるデュシェンヌ筋ジストロフィーの種類別市場規模：エクソンディス、エンフラザ、トランスラーナ - 中国におけるデュシェンヌ筋ジストロフィーの用途別市場規模：病院、診療所、在宅医療 ・デュシェンヌ筋ジストロフィーの北米市場（2016年-2027年） ・デュシェンヌ筋ジストロフィーのヨーロッパ市場（2016年-2027年） ・デュシェンヌ筋ジストロフィーのアジア太平洋市場（2016年-2027年） ・デュシェンヌ筋ジストロフィーの中南米市場（2016年-2027年） ・デュシェンヌ筋ジストロフィーの中東・アフリカ市場（2016年-2027年） ・主要プレイヤーの情報：Sarepta Therapeutics、PTC Therapeutics、Pfizer、Bristol-Myers Squibb、Italfarmaco、Santhera Pharmaceuticals ・市場機会・課題・リスク要因分析 ・バリューチェーン・販売チャネル分析 ・... |
uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys’ respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.
Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.
North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.
In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.
Market Analysis and Insights: Global and China Duchenne Muscular Dystrophy Market
This report focuses on global and China Duchenne Muscular Dystrophy market.
In 2020, the global Duchenne Muscular Dystrophy market size was US$ 935 million and it is expected to reach US$ 9904.4 million by the end of 2027, with a CAGR of 42.1% during 2021-2027. In China the Duchenne Muscular Dystrophy market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.
Global Duchenne Muscular Dystrophy Scope and Market Size
Duchenne Muscular Dystrophy market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Duchenne Muscular Dystrophy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For China market, this report focuses on the Duchenne Muscular Dystrophy market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.
Segment by Type
Exondys 51
Emflaza
Translarna
Segment by Application
Hospitals
Clinics
Home Care
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
1 Study Coverage
1.1 Duchenne Muscular Dystrophy Product Introduction
1.2 Market by Type
1.2.1 Global Duchenne Muscular Dystrophy Market Size Growth Rate by Type
1.2.2 Exondys 51
1.2.3 Emflaza
1.2.4 Translarna
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy Market Size Growth Rate by Application
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Duchenne Muscular Dystrophy Market Size, Estimates and Forecasts
2.1.1 Global Duchenne Muscular Dystrophy Revenue 2016-2027
2.1.2 Global Duchenne Muscular Dystrophy Sales 2016-2027
2.2 Global Duchenne Muscular Dystrophy, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Duchenne Muscular Dystrophy Historical Market Size by Region (2016-2021)
2.3.1 Global Duchenne Muscular Dystrophy Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Duchenne Muscular Dystrophy Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Duchenne Muscular Dystrophy Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Duchenne Muscular Dystrophy Sales Forecast by Region (2022-2027)
2.4.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Region (2022-2027)
3 Global Duchenne Muscular Dystrophy Competitor Landscape by Players
3.1 Global Top Duchenne Muscular Dystrophy Manufacturers by Sales
3.1.1 Global Duchenne Muscular Dystrophy Sales by Manufacturer (2016-2021)
3.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Duchenne Muscular Dystrophy Manufacturers by Revenue
3.2.1 Key Duchenne Muscular Dystrophy Manufacturers Covered: Ranking by Revenue
3.2.2 Global Duchenne Muscular Dystrophy Revenue by Manufacturers (2016-2021)
3.2.3 Global Duchenne Muscular Dystrophy Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Duchenne Muscular Dystrophy Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Revenue in 2020
3.2.6 Global Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Duchenne Muscular Dystrophy Price by Manufacturers
3.4 Global Duchenne Muscular Dystrophy Manufacturing Base Distribution, Product Types
3.4.1 Duchenne Muscular Dystrophy Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Duchenne Muscular Dystrophy Product Type
3.4.3 Date of International Manufacturers Enter into Duchenne Muscular Dystrophy Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2016-2027)
4.1 Global Duchenne Muscular Dystrophy Market Size by Type (2016-2021)
4.1.1 Global Duchenne Muscular Dystrophy Sales by Type (2016-2021)
4.1.2 Global Duchenne Muscular Dystrophy Revenue by Type (2016-2021)
4.1.3 Duchenne Muscular Dystrophy Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Duchenne Muscular Dystrophy Market Size Forecast by Type (2022-2027)
4.2.1 Global Duchenne Muscular Dystrophy Sales Forecast by Type (2022-2027)
4.2.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Type (2022-2027)
4.2.3 Duchenne Muscular Dystrophy Average Selling Price (ASP) Forecast by Type (2022-2027)
5 Breakdown Data by Application (2016-2027)
5.1 Global Duchenne Muscular Dystrophy Market Size by Application (2016-2021)
5.1.1 Global Duchenne Muscular Dystrophy Sales by Application (2016-2021)
5.1.2 Global Duchenne Muscular Dystrophy Revenue by Application (2016-2021)
5.1.3 Duchenne Muscular Dystrophy Price by Application (2016-2021)
5.2 Duchenne Muscular Dystrophy Market Size Forecast by Application (2022-2027)
5.2.1 Global Duchenne Muscular Dystrophy Sales Forecast by Application (2022-2027)
5.2.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Application (2022-2027)
5.2.3 Global Duchenne Muscular Dystrophy Price Forecast by Application (2022-2027)
6 China by Players, Type and Application
6.1 China Duchenne Muscular Dystrophy Market Size YoY Growth 2016-2027
6.1.1 China Duchenne Muscular Dystrophy Sales YoY Growth 2016-2027
6.1.2 China Duchenne Muscular Dystrophy Revenue YoY Growth 2016-2027
6.1.3 China Duchenne Muscular Dystrophy Market Share in Global Market 2016-2027
6.2 China Duchenne Muscular Dystrophy Market Size by Players (International and Local Players)
6.2.1 China Top Duchenne Muscular Dystrophy Players by Sales (2016-2021)
6.2.2 China Top Duchenne Muscular Dystrophy Players by Revenue (2016-2021)
6.3 China Duchenne Muscular Dystrophy Historic Market Review by Type (2016-2021)
6.3.1 China Duchenne Muscular Dystrophy Sales Market Share by Type (2016-2021)
6.3.2 China Duchenne Muscular Dystrophy Revenue Market Share by Type (2016-2021)
6.3.3 China Duchenne Muscular Dystrophy Price by Type (2016-2021)
6.4 China Duchenne Muscular Dystrophy Market Estimates and Forecasts by Type (2022-2027)
6.4.1 China Duchenne Muscular Dystrophy Sales Forecast by Type (2022-2027)
6.4.2 China Duchenne Muscular Dystrophy Revenue Forecast by Type (2022-2027)
6.4.3 China Duchenne Muscular Dystrophy Price Forecast by Type (2022-2027)
6.5 China Duchenne Muscular Dystrophy Historic Market Review by Application (2016-2021)
6.5.1 China Duchenne Muscular Dystrophy Sales Market Share by Application (2016-2021)
6.5.2 China Duchenne Muscular Dystrophy Revenue Market Share by Application (2016-2021)
6.5.3 China Duchenne Muscular Dystrophy Price by Application (2016-2021)
6.6 China Duchenne Muscular Dystrophy Market Estimates and Forecasts by Application (2022-2027)
6.6.1 China Duchenne Muscular Dystrophy Sales Forecast by Application (2022-2027)
6.6.2 China Duchenne Muscular Dystrophy Revenue Forecast by Application (2022-2027)
6.6.3 China Duchenne Muscular Dystrophy Price Forecast by Application (2022-2027)
7 North America
7.1 North America Duchenne Muscular Dystrophy Market Size YoY Growth 2016-2027
7.2 North America Duchenne Muscular Dystrophy Market Facts & Figures by Country
7.2.1 North America Duchenne Muscular Dystrophy Sales by Country (2016-2021)
7.2.2 North America Duchenne Muscular Dystrophy Revenue by Country (2016-2021)
7.2.3 U.S.
7.2.4 Canada
8 Asia Pacific
8.1 Asia Pacific Duchenne Muscular Dystrophy Market Size YoY Growth 2016-2027
8.2 Asia Pacific Duchenne Muscular Dystrophy Market Facts & Figures by Region
8.2.1 Asia Pacific Duchenne Muscular Dystrophy Sales by Region (2016-2021)
8.2.2 Asia Pacific Duchenne Muscular Dystrophy Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
8.2.12 Philippines
8.2.13 Vietnam
9 Europe
9.1 Europe Duchenne Muscular Dystrophy Market Size YoY Growth 2016-2027
9.2 Europe Duchenne Muscular Dystrophy Market Facts & Figures by Country
9.2.1 Europe Duchenne Muscular Dystrophy Sales by Country (2016-2021)
9.2.2 Europe Duchenne Muscular Dystrophy Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy
10 Latin America
10.1 Latin America Duchenne Muscular Dystrophy Market Size YoY Growth 2016-2027
10.2 Latin America Duchenne Muscular Dystrophy Market Facts & Figures by Country
10.2.1 Latin America Duchenne Muscular Dystrophy Sales by Country (2016-2021)
10.2.2 Latin America Duchenne Muscular Dystrophy Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Duchenne Muscular Dystrophy Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Duchenne Muscular Dystrophy Market Facts & Figures by Country
11.2.1 Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2016-2021)
11.2.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Sarepta Therapeutics
12.1.1 Sarepta Therapeutics Corporation Information
12.1.2 Sarepta Therapeutics Description and Business Overview
12.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Products Offered
12.1.5 Sarepta Therapeutics Recent Development
12.2 PTC Therapeutics
12.2.1 PTC Therapeutics Corporation Information
12.2.2 PTC Therapeutics Description and Business Overview
12.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2016-2021)
12.2.4 PTC Therapeutics Duchenne Muscular Dystrophy Products Offered
12.2.5 PTC Therapeutics Recent Development
12.3 Pfizer
12.3.1 Pfizer Corporation Information
12.3.2 Pfizer Description and Business Overview
12.3.3 Pfizer Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Pfizer Duchenne Muscular Dystrophy Products Offered
12.3.5 Pfizer Recent Development
12.4 Bristol-Myers Squibb
12.4.1 Bristol-Myers Squibb Corporation Information
12.4.2 Bristol-Myers Squibb Description and Business Overview
12.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Products Offered
12.4.5 Bristol-Myers Squibb Recent Development
12.5 Italfarmaco
12.5.1 Italfarmaco Corporation Information
12.5.2 Italfarmaco Description and Business Overview
12.5.3 Italfarmaco Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Italfarmaco Duchenne Muscular Dystrophy Products Offered
12.5.5 Italfarmaco Recent Development
12.6 Santhera Pharmaceuticals
12.6.1 Santhera Pharmaceuticals Corporation Information
12.6.2 Santhera Pharmaceuticals Description and Business Overview
12.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Products Offered
12.6.5 Santhera Pharmaceuticals Recent Development
12.11 Sarepta Therapeutics
12.11.1 Sarepta Therapeutics Corporation Information
12.11.2 Sarepta Therapeutics Description and Business Overview
12.11.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Products Offered
12.11.5 Sarepta Therapeutics Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Duchenne Muscular Dystrophy Industry Trends
13.2 Duchenne Muscular Dystrophy Market Drivers
13.3 Duchenne Muscular Dystrophy Market Challenges
13.4 Duchenne Muscular Dystrophy Market Restraints
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Duchenne Muscular Dystrophy Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Global Duchenne Muscular Dystrophy Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Exondys 51
Table 3. Major Manufacturers of Emflaza
Table 4. Major Manufacturers of Translarna
Table 5. Global Duchenne Muscular Dystrophy Market Size Growth Rate by Application (2021-2027) & (K Doses)
Table 6. Global Duchenne Muscular Dystrophy Market Size by Region (K Doses) & (US$ Million), 2016 VS 2021 VS 2027
Table 7. Global Duchenne Muscular Dystrophy Sales by Regions (2016-2021) & (K Doses)
Table 8. Global Duchenne Muscular Dystrophy Sales Market Share by Regions (2016-2021)
Table 9. Global Duchenne Muscular Dystrophy Revenue by Regions (2016-2021) & (US$ Million)
Table 10. Global Duchenne Muscular Dystrophy Sales Forecast by Region (2022-2027) & (K Doses)
Table 11. Global Duchenne Muscular Dystrophy Sales Market Share Forecast by Region (2022-2027)
Table 12. Global Duchenne Muscular Dystrophy Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 13. Global Duchenne Muscular Dystrophy Revenue Market Share Forecast by Region (2022-2027)
Table 14. Global Duchenne Muscular Dystrophy Sales by Manufacturers (2016-2021) (K Doses)
Table 15. Global Duchenne Muscular Dystrophy Sales Share by Manufacturers (2016-2021)
Table 16. Ranking of Global Top Duchenne Muscular Dystrophy Manufacturers by Revenue (US$ Million) in 2020
Table 17. Duchenne Muscular Dystrophy Revenue by Manufacturers (2016-2021) (US$ Million)
Table 18. Duchenne Muscular Dystrophy Revenue Share by Manufacturers (2016-2021)
Table 19. Global Duchenne Muscular Dystrophy Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 20. Global Duchenne Muscular Dystrophy by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Duchenne Muscular Dystrophy as of 2020)
Table 21. Key Manufacturers Duchenne Muscular Dystrophy Price (2016-2021) (USD/Dose)
Table 22. Duchenne Muscular Dystrophy Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Duchenne Muscular Dystrophy Product Type
Table 24. Date of International Manufacturers Enter into Duchenne Muscular Dystrophy Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Duchenne Muscular Dystrophy Sales by Type (2016-2021) (K Doses)
Table 27. Global Duchenne Muscular Dystrophy Sales Share by Type (2016-2021)
Table 28. Global Duchenne Muscular Dystrophy Revenue by Type (2016-2021) (US$ Million)
Table 29. Global Duchenne Muscular Dystrophy Revenue Share by Type (2016-2021)
Table 30. Duchenne Muscular Dystrophy Average Selling Price (ASP) by Type (2016-2021) & (USD/Dose)
Table 31. Global Duchenne Muscular Dystrophy Sales Forecast by Type (2022-2027) & (K Doses)
Table 32. Global Duchenne Muscular Dystrophy Sales Market Share Forecast by Type (2022-2027)
Table 33. Global Duchenne Muscular Dystrophy Revenue Forecast V (2022-2027) & (US$ Million)
Table 34. Global Duchenne Muscular Dystrophy Revenue Market Share Forecast by Type (2022-2027)
Table 35. Global Duchenne Muscular Dystrophy Average Selling Price (ASP) Forecast by Type (2022-2027) & (USD/Dose)
Table 36. Global Duchenne Muscular Dystrophy Sales by Application (2016-2021) (K Doses)
Table 37. Global Duchenne Muscular Dystrophy Sales Share by Application (2016-2021)
Table 38. Global Duchenne Muscular Dystrophy Revenue by Application (2016-2021) (US$ Million)
Table 39. Global Duchenne Muscular Dystrophy Revenue Share by Application (2016-2021)
Table 40. Duchenne Muscular Dystrophy Average Selling Price (ASP) by Application (2016-2021) & (USD/Dose)
Table 41. Global Duchenne Muscular Dystrophy Sales Forecast by Application (2022-2027) & (K Doses)
Table 42. Global Duchenne Muscular Dystrophy Sales Market Share Forecast by Application (2022-2027)
Table 43. Global Duchenne Muscular Dystrophy Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 44. Global Duchenne Muscular Dystrophy Revenue Market Share Forecast by Application (2022-2027)
Table 45. Global Duchenne Muscular Dystrophy Average Selling Price (ASP) Forecast by Application (2022-2027) & (USD/Dose)
Table 46. China Duchenne Muscular Dystrophy Sales (K Doses) of Key Companies (2016-2021)
Table 47. China Duchenne Muscular Dystrophy Sales Share by Company (2016-2021)
Table 48. China Duchenne Muscular Dystrophy Revenue (US$ Million) by Company (2016-2021)
Table 49. China Duchenne Muscular Dystrophy Revenue Share by Company (2016-2021)
Table 50. China Duchenne Muscular Dystrophy Sales (K Doses) by Type (2016-2021)
Table 51. China Duchenne Muscular Dystrophy Sales Share by Type (2016-2021)
Table 52. China Duchenne Muscular Dystrophy Revenue (US$ Million) Market Share by Type (2016-2021)
Table 53. China Duchenne Muscular Dystrophy Price (USD/Dose) by Type (2016-2021)
Table 54. China Duchenne Muscular Dystrophy Sales (K Doses) by Type (2022-2027)
Table 55. China Duchenne Muscular Dystrophy Sales Share by Type (2022-2027)
Table 56. China Duchenne Muscular Dystrophy Revenue (US$ Million) Market Share by Type (2022-2027)
Table 57. China Duchenne Muscular Dystrophy Revenue Share by Type (2022-2027)
Table 58. China Duchenne Muscular Dystrophy Price (USD/Dose) by Type (2022-2027)
Table 59. China Duchenne Muscular Dystrophy Sales (K Doses) by Application (2016-2021)
Table 60. China Duchenne Muscular Dystrophy Sales Share by Application (2016-2021)
Table 61. China Duchenne Muscular Dystrophy Revenue (US$ Million) Market Share by Application (2016-2021)
Table 62. China Duchenne Muscular Dystrophy Price (USD/Dose) by Application (2016-2021)
Table 63. China Duchenne Muscular Dystrophy Sales (K Doses) by Application (2022-2027)
Table 64. China Duchenne Muscular Dystrophy Sales Share by Application (2022-2027)
Table 65. China Duchenne Muscular Dystrophy Revenue (US$ Million) Market Share by Application (2022-2027)
Table 66. China Duchenne Muscular Dystrophy Revenue Share by Application (2022-2027)
Table 67. China Duchenne Muscular Dystrophy Price (USD/Dose) by Application (2022-2027)
Table 68. North America Duchenne Muscular Dystrophy Sales by Country (2016-2021) & (K Doses)
Table 69. North America Duchenne Muscular Dystrophy Sales Market Share by Country (2016-2021)
Table 70. North America Duchenne Muscular Dystrophy Revenue by Country (2016-2021) & (US$ Million)
Table 71. North America Duchenne Muscular Dystrophy Revenue Market Share by Country (2016-2021)
Table 72. Asia Pacific Duchenne Muscular Dystrophy Sales by Region (2016-2021) & (K Doses)
Table 73. Asia Pacific Duchenne Muscular Dystrophy Sales Market Share by Region (2016-2021)
Table 74. Asia Pacific Duchenne Muscular Dystrophy Revenue by Region (2016-2021) & (US$ Million)
Table 75. Asia Pacific Duchenne Muscular Dystrophy Revenue Market Share by Region (2016-2021)
Table 76. Europe Duchenne Muscular Dystrophy Sales by Country (2016-2021) & (K Doses)
Table 77. Europe Duchenne Muscular Dystrophy Sales Market Share by Country (2016-2021)
Table 78. Europe Duchenne Muscular Dystrophy Revenue by Country (2016-2021) & (US$ Million)
Table 79. Europe Duchenne Muscular Dystrophy Revenue Market Share by Country (2016-2021)
Table 80. Latin America Duchenne Muscular Dystrophy Sales by Country (2016-2021) & (K Doses)
Table 81. Latin America Duchenne Muscular Dystrophy Sales Market Share by Country (2016-2021)
Table 82. Latin Americaa Duchenne Muscular Dystrophy Revenue by Country (2016-2021) & (US$ Million)
Table 83. Latin America Duchenne Muscular Dystrophy Revenue Market Share by Country (2016-2021)
Table 84. Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2016-2021) & (K Doses)
Table 85. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share by Country (2016-2021)
Table 86. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2016-2021) & (US$ Million)
Table 87. Middle East and Africa Duchenne Muscular Dystrophy Revenue Market Share by Country (2016-2021)
Table 88. Sarepta Therapeutics Corporation Information
Table 89. Sarepta Therapeutics Description and Business Overview
Table 90. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 91. Sarepta Therapeutics Duchenne Muscular Dystrophy Product
Table 92. Sarepta Therapeutics Recent Development
Table 93. PTC Therapeutics Corporation Information
Table 94. PTC Therapeutics Description and Business Overview
Table 95. PTC Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 96. PTC Therapeutics Product
Table 97. PTC Therapeutics Recent Development
Table 98. Pfizer Corporation Information
Table 99. Pfizer Description and Business Overview
Table 100. Pfizer Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 101. Pfizer Product
Table 102. Pfizer Recent Development
Table 103. Bristol-Myers Squibb Corporation Information
Table 104. Bristol-Myers Squibb Description and Business Overview
Table 105. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 106. Bristol-Myers Squibb Product
Table 107. Bristol-Myers Squibb Recent Development
Table 108. Italfarmaco Corporation Information
Table 109. Italfarmaco Description and Business Overview
Table 110. Italfarmaco Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 111. Italfarmaco Product
Table 112. Italfarmaco Recent Development
Table 113. Santhera Pharmaceuticals Corporation Information
Table 114. Santhera Pharmaceuticals Description and Business Overview
Table 115. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 116. Santhera Pharmaceuticals Product
Table 117. Santhera Pharmaceuticals Recent Development
Table 118. Duchenne Muscular Dystrophy Market Trends
Table 119. Duchenne Muscular Dystrophy Market Drivers
Table 120. Duchenne Muscular Dystrophy Market Challenges
Table 121. Duchenne Muscular Dystrophy Market Restraints
Table 122. Duchenne Muscular Dystrophy Customers List
Table 123. Duchenne Muscular Dystrophy Distributors List
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Duchenne Muscular Dystrophy Product Picture
Figure 2. Global Duchenne Muscular Dystrophy Sales Market Share by Type in 2020 & 2027
Figure 3. Exondys 51 Product Picture
Figure 4. Emflaza Product Picture
Figure 5. Translarna Product Picture
Figure 6. Global Duchenne Muscular Dystrophy Sales Market Share by Application in 2020 & 2027
Figure 7. Hospitals
Figure 8. Clinics
Figure 9. Home Care
Figure 10. Duchenne Muscular Dystrophy Report Years Considered
Figure 11. Global Duchenne Muscular Dystrophy Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Duchenne Muscular Dystrophy Market Size 2016-2027 (US$ Million)
Figure 13. Global Duchenne Muscular Dystrophy Sales 2016-2027 (K Doses)
Figure 14. Global Duchenne Muscular Dystrophy Market Size Market Share by Region: 2021 Versus 2027
Figure 15. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2016-2021)
Figure 16. Global Duchenne Muscular Dystrophy Sales Market Share by Region in 2020
Figure 17. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2016-2021)
Figure 18. Global Duchenne Muscular Dystrophy Revenue Market Share by Region in 2020
Figure 19. Global Duchenne Muscular Dystrophy Sales Share by Manufacturer in 2020
Figure 20. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Revenue in 2020
Figure 21. Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 22. Global Duchenne Muscular Dystrophy Sales Market Share by Type (2016-2021)
Figure 23. Global Duchenne Muscular Dystrophy Sales Market Share by Type in 2020
Figure 24. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2016-2021)
Figure 25. Global Duchenne Muscular Dystrophy Revenue Market Share by Type in 2020
Figure 26. Global Duchenne Muscular Dystrophy Sales Market Share by Application (2016-2021)
Figure 27. Global Duchenne Muscular Dystrophy Sales Market Share by Application in 2020
Figure 28. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2016-2021)
Figure 29. Global Duchenne Muscular Dystrophy Revenue Market Share by Application in 2020
Figure 30. China Duchenne Muscular Dystrophy Sales Growth Rate 2016-2027 (K Doses)
Figure 31. China Duchenne Muscular Dystrophy Revenue Growth Rate 2016-2027 (US$ Million)
Figure 32. China Duchenne Muscular Dystrophy Market Share in Global Market 2016-2027
Figure 33. China 5 and 10 Largest Duchenne Muscular Dystrophy Players Market Share by Revenue in Duchenne Muscular Dystrophy in 2020
Figure 34. China Duchenne Muscular Dystrophy Revenue Share by Type (2016-2021)
Figure 35. China Duchenne Muscular Dystrophy Revenue Growth Rate by Type in 2016 & 2020
Figure 36. China Duchenne Muscular Dystrophy Revenue Share by Application (2016-2021)
Figure 37. China Duchenne Muscular Dystrophy Revenue Growth Rate by Application in 2016 & 2020
Figure 38. North America Duchenne Muscular Dystrophy Sales Growth Rate 2016-2021 (K Doses)
Figure 39. North America Duchenne Muscular Dystrophy Revenue Growth Rate 2016-2021 (US$ Million)
Figure 40. North America Duchenne Muscular Dystrophy Sales Market Share by Country in 2020
Figure 41. North America Duchenne Muscular Dystrophy Revenue Market Share by Country in 2020
Figure 42. U.S. Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 43. U.S. Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Canada Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 45. Canada Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Europe Duchenne Muscular Dystrophy Sales Growth Rate 2016-2021 (K Doses)
Figure 47. Europe Duchenne Muscular Dystrophy Revenue Growth Rate 2016-2021 (US$ Million)
Figure 48. Europe Duchenne Muscular Dystrophy Sales Market Share by Country in 2020
Figure 49. Europe Duchenne Muscular Dystrophy Revenue Market Share by Country in 2020
Figure 50. Germany Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 51. Germany Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 52. France Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 53. France Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 54. U.K. Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 55. U.K. Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 56. Italy Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 57. Italy Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 58. Russia Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 59. Russia Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 60. Asia Pacific Duchenne Muscular Dystrophy Sales Growth Rate 2016-2021 (K Doses)
Figure 61. Asia Pacific Duchenne Muscular Dystrophy Revenue Growth Rate 2016-2021 (US$ Million)
Figure 62. Asia Pacific Duchenne Muscular Dystrophy Sales Market Share by Region in 2020
Figure 63. Asia Pacific Duchenne Muscular Dystrophy Revenue Market Share by Region in 2020
Figure 64. China Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 65. China Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 66. Japan Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 67. Japan Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 68. South Korea Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 69. South Korea Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 70. India Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 71. India Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 72. Australia Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 73. Australia Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 74. Taiwan Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 75. Taiwan Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 76. Indonesia Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 77. Indonesia Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 78. Thailand Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 79. Thailand Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 80. Malaysia Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 81. Malaysia Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 82. Philippines Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 83. Philippines Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 84. Vietnam Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 85. Vietnam Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 86. Latin America Duchenne Muscular Dystrophy Sales Growth Rate 2016-2021 (K Doses)
Figure 87. Latin America Duchenne Muscular Dystrophy Revenue Growth Rate 2016-2021 (US$ Million)
Figure 88. Latin America Duchenne Muscular Dystrophy Sales Market Share by Country in 2020
Figure 89. Latin America Duchenne Muscular Dystrophy Revenue Market Share by Country in 2020
Figure 90. Mexico Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 91. Mexico Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 92. Brazil Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 93. Brazil Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 94. Argentina Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 95. Argentina Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 96. Middle East and Africa Duchenne Muscular Dystrophy Sales Growth Rate 2016-2021 (K Doses)
Figure 97. Middle East and Africa Duchenne Muscular Dystrophy Revenue Growth Rate 2016-2021 (US$ Million)
Figure 98. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share by Country in 2020
Figure 99. Middle East and Africa Duchenne Muscular Dystrophy Revenue Market Share by Country in 2020
Figure 100. Turkey Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 101. Turkey Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 102. Saudi Arabia Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 103. Saudi Arabia Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 104. U.A.E Duchenne Muscular Dystrophy Sales Growth Rate (2016-2021) (K Doses)
Figure 105. U.A.E Duchenne Muscular Dystrophy Revenue Growth Rate (2016-2021) (US$ Million)
Figure 106. Duchenne Muscular Dystrophy Value Chain
Figure 107. Channels of Distribution
Figure 108. Distributors Profiles
Figure 109. Bottom-up and Top-down Approaches for This Report
Figure 110. Data Triangulation
Figure 111. Key Executives Interviewed
デュシェンヌ型筋ジストロフィー（DMD）治療の世界市場 2020年 Market Overview The Duchenne Muscular Dystrophy (DMD) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, …- ベッカー型筋ジストロフィー治療薬の世界市場 2020年 Market Overview The global Becker Muscular Dystrophy Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Becker Muscula…
- 筋緊張性ジストロフィー薬の世界市場 2020年 Market Overview The global Myotonic Dystrophy Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Myotonic Dystrophy Dr…
- インスリン様成長因子Iの世界市場 2020年 Market Overview The global Insulin Like Growth Factor I market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Insulin Like Gro…
- 解剖モデルの世界市場 2020年 Market Overview The Anatomical Models market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, tra…